Drugs / RE03
last change Aug 2026 re-read 3 minutes ago

RE03

Developed for
insomnia · post-traumatic stress disorder
Investigated by
Reconnect Labs · University of Zurich

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06685965 Sep 2025 → Aug 2026 overdue insomnia, post-traumatic stress disorder Reconnect Labs Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RE03 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06685965 ↗